Summary of Key Points Core Viewpoint - Multiple shareholders across various companies are planning to reduce their holdings, indicating potential shifts in investor sentiment and market dynamics. Shareholder Reductions - Xiamen Chentu and its concerted parties plan to reduce holdings by up to 4.027 million shares in Xiaoming Co [1] - Guoxin Jianyuan and Jianxin Investment intend to collectively reduce holdings by up to 26.7516 million shares in Hongsheng Huayuan [1] - Founder Information Industry plans to reduce up to 3% of its shares in Founder Technology [1] - The controlling shareholder of Tongguang Cable intends to reduce up to 3% of its shares [1] - Li Jianwei plans to reduce up to 3.2 million shares in Mengjie Co [1] - Sun Xiujie plans to reduce up to 3% of shares in Xinyaqiang [1] - The controlling shareholder of Galaxy Electronics intends to reduce up to 0.81% of its shares [1] - Guangda Investment and Jingwei Investment plan to collectively reduce 4.6443 million shares in Ningbo Jingda [1] - Haishuo Development and Ningbo Hechuang plan to collectively reduce 1.7156 million shares in Sanboshuo [1] - Youlijia Partnership plans to reduce 5.122 million shares in Pioneer Precision [1] - Qizhong Shiyuan has already reduced 5.8036 million shares in Nanwei Software [1] Financial Performance - Zhixiang Jintai is projected to incur a net loss of 536 million yuan in 2025 [1] - Trina Solar is projected to incur a net loss of 6.994 billion yuan in 2025 [1]

Core Viewpoint - Zhixiang Jintai announced that it expects to achieve a total operating revenue of 230,722,204.02 yuan in 2025, representing a year-on-year growth of 666.65% [2] Financial Performance - The net profit attributable to the parent company's owners is projected to be -536,220,722.04 yuan, with losses narrowing by 32.74% year-on-year [2]

Core Viewpoint - Zhixiang Jintai (688443.SH) reported a significant increase in total operating revenue for the fiscal year 2025, while narrowing its net loss, indicating positive momentum in its business operations [1] Financial Performance - The company achieved total operating revenue of 231 million yuan, representing a year-on-year growth of 666.65% [1] - Operating profit loss narrowed by 33.57% compared to the previous year [1] - Total profit loss decreased by 32.74% year-on-year [1] - Net profit attributable to the parent company's owners showed a reduction in loss by 32.74% compared to the same period last year [1] Product Development and Market Expansion - The growth in revenue is primarily attributed to the market expansion of the company's first commercialized product, Saliqi monoclonal antibody injection (Jinlixi®), which saw steady sales growth [1] - Significant licensing income from the GR1803 injection's licensing and commercialization agreement positively impacted the company's net profit for the period [1]

Core Viewpoint - Zhixiang Jintai (688443.SH) reported a significant increase in total operating revenue for the year 2025, while narrowing its net loss, indicating positive developments in its commercial product sales and licensing agreements [1] Group 1: Financial Performance - The company achieved total operating revenue of 231 million, representing a year-on-year increase of 666.65% [1] - The operating loss narrowed by 33.57% compared to the previous year [1] - The total profit loss decreased by 32.74% year-on-year [1] - The net profit attributable to the parent company owners showed a reduction in loss by 32.74% compared to the same period last year [1] Group 2: Product and Market Development - The growth in revenue is primarily attributed to the expansion of the sales market for its first commercial product, Saliqi monoclonal antibody injection (Jinlixi) [1] - The licensing income from the GR1803 injection's authorization and commercialization agreement had a significant positive impact on the company's net profit for the period [1]

Group 1 - The core viewpoint of the news is that Zhixiang Jintai has been consistently operating at a loss since its establishment, with significant losses reported in recent years, indicating challenges in achieving profitability [2] - For the fiscal year 2025, Zhixiang Jintai reported an operating revenue of 231 million yuan, a substantial increase of 666.65% year-on-year, while the net profit attributable to shareholders was a loss of 536 million yuan, which is a 32.74% improvement compared to the previous year [1] - The company's total assets at the end of the reporting period were approximately 2.99 billion yuan, reflecting a decrease of 4.87% year-on-year, and the equity attributable to shareholders decreased by 25.49% to approximately 1.58 billion yuan [1] Group 2 - The significant revenue growth is attributed to the market expansion of the company's first commercial product, the monoclonal antibody injection, and substantial licensing income from the GR1803 injection commercialization agreement, positively impacting the net profit for the period [1] - Zhixiang Jintai has been in a loss-making state since its inception in 2015, with net profits for the years 2019 to 2024 recorded as -158 million yuan, -373 million yuan, -322 million yuan, -576 million yuan, -801 million yuan, and -797 million yuan respectively, indicating a trend of increasing losses [2]

证券代码：688443 证券简称：智翔金泰 公告编号：2026-009 重庆智翔金泰生物制药股份有限公司 自愿披露关于泰利奇拜单抗注射液成人季节性过敏 性鼻炎适应症上市申请获得受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，重庆智翔金泰生物制药股份有限公司（以下简称"公司"）的泰利奇 拜单抗注射液（GR1802 注射液）用于成人季节性过敏性鼻炎适应症 III 期临床 试验达到了主要终点指标，公司向国家药品监督管理局（NMPA）药品审评中心 （CDE）提交了该适应症的新药上市申请并获得受理。 一、药品基本信息 药品名称：泰利奇拜单抗注射液 申请事项：境内生产药品注册上市许可 申请人：重庆智翔金泰生物制药股份有限公司 审批结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 二、药品其他相关情况 泰利奇拜单抗注射液（GR1802 注射液）是一款由公司自主研发的重组全人 源抗 IL-4Rα单克隆抗体，作用靶点为 IL-4Rα。泰利奇拜单抗注射液能特异性结 合细胞表面人 IL-4Rα，阻断 ...

Financial Performance - The total operating revenue for 2025 reached RMB 230.72 million, a significant increase of 666.65% compared to RMB 30.09 million in the same period last year[3] - The net profit attributable to the parent company was a loss of RMB 536.22 million, which is a 32.74% reduction in losses compared to RMB 797.27 million in the previous year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was a loss of RMB 579.22 million, narrowing losses by 27.99% from RMB 804.33 million year-on-year[3] - The basic earnings per share decreased by 32.26% to RMB -1.47 from RMB -2.17 in the previous year[3] - The company reported a weighted average return on net assets of -28.93%, an improvement of 3.72 percentage points from -32.65% in the previous year[3] Assets and Equity - Total assets at the end of the reporting period were RMB 2,992.66 million, down 4.87% from RMB 3,145.72 million at the beginning of the period[3] - Equity attributable to the parent company decreased by 25.49% to RMB 1,584.20 million from RMB 2,126.04 million year-on-year[3] Revenue Growth Drivers - The company attributed the revenue growth to the market expansion of its first commercialized product, the Saliqi monoclonal antibody injection (Jinlixi®), which saw steady sales growth[6] - The significant increase in revenue was also supported by substantial licensing income from the GR1803 injection commercialization agreement[6] Financial Reporting - The financial data presented is preliminary and unaudited, with final results to be disclosed in the 2025 annual report[4]

Core Viewpoint - The company, Zhixiang Jintai, has achieved a significant milestone with its drug, GR1802 injection, for the treatment of adult seasonal allergic rhinitis, successfully reaching the primary endpoint in Phase III clinical trials and has submitted a new drug application to the National Medical Products Administration (NMPA) [1] Group 1 - GR1802 injection is a fully humanized monoclonal antibody targeting IL-4Rα, designed to inhibit Th2-type inflammatory responses by blocking the binding of IL-4 and IL-13 to IL-4Rα [1] - The new drug application for GR1802 injection for moderate to severe atopic dermatitis in adults was accepted in September 2025, indicating ongoing development in this area [1] - Multiple indications for GR1802 injection are currently in clinical trial stages, including chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria in Phase III, and asthma in Phase II [1] Group 2 - As of the announcement date, only two other drugs targeting the same pathway have been approved for marketing in China, highlighting the competitive landscape for GR1802 injection [2]

Core Viewpoint - The company reported significant revenue growth for the fiscal year 2025, with total operating revenue reaching 230.72 million, a year-on-year increase of 666.65%. However, it also reported a net loss attributable to the parent company of 536.22 million, although this loss has narrowed by 32.74% compared to the previous year [1]. Financial Performance - Total operating revenue for 2025 was 230.72 million, reflecting a substantial increase of 666.65% year-on-year [1]. - The net profit attributable to the parent company was -536.22 million, indicating a reduction in losses by 32.74% [1]. - The non-recurring net profit was -579.22 million, with a loss reduction of 27.99% [1]. Asset and Equity Position - At the end of the reporting period, total assets amounted to 2,992.66 million, which represents a decrease of 4.87% year-on-year [1]. - The equity attributable to the parent company's owners was 1,584.20 million, showing a decline of 25.49% compared to the previous year [1]. Revenue Drivers - The growth in revenue and the narrowing of losses were primarily driven by an increase in product sales revenue and an uptick in licensing income [1].

Core Viewpoint - Zhixiang Jintai (688443.SH) reported significant growth in revenue for the fiscal year 2025, with total operating revenue reaching 231 million yuan, marking a 666.65% increase compared to the previous year. However, the company still recorded a net loss of 536 million yuan, although this loss has narrowed by 32.74% year-on-year [1]. Financial Performance - The company achieved total operating revenue of 231 million yuan, representing a year-on-year growth of 666.65% [1]. - The operating profit showed a year-on-year loss reduction of 33.57% [1]. - The total profit also saw a year-on-year loss reduction of 32.74% [1]. - The net profit attributable to the parent company was a loss of 536 million yuan, which is a 32.74% reduction in loss compared to the previous year [1]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, was a loss of 579 million yuan, reflecting a 27.99% reduction in loss year-on-year [1]. Key Drivers - The significant revenue growth is primarily attributed to the expansion of the sales market for the company's first commercialized product, Saliqi monoclonal antibody injection (Jinlixi®), which has shown steady growth in sales revenue compared to the previous year [1]. - The revenue from the licensing and commercialization agreement for GR1803 injection has also positively impacted the company's net profit for the current period due to substantial licensing income [1].